Jenny Doss
Family · Jasper, ALNPI 1700869609
Payments from drug & device makers
Across 75 payments — averaging $16.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$386
- Amarin Pharma, Inc.$197
- Bayer$109
- Vifor Pharma, Inc.$74
- Alnylam Pharmaceuticals Inc.$56
- Paratek Pharmaceuticals, Inc.$48
- plus $369 from 15 others
What the payments were for
- Food & beverage$1,22499%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 27 | $386 |
| Amarin Pharma, Inc. | 13 | $197 |
| Bayer | 7 | $109 |
| Vifor Pharma, Inc. | 4 | $74 |
| Alnylam Pharmaceuticals Inc. | 1 | $56 |
| Paratek Pharmaceuticals, Inc. | 1 | $48 |
| AstraZeneca | 3 | $48 |
| Jazz Pharmaceuticals Inc. | 3 | $47 |
| UCB, Inc. | 2 | $40 |
| Amgen | 2 | $35 |
| Pfizer | 2 | $30 |
| Ambu Inc. | 1 | $29 |
| Novo Nordisk | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Calliditas Therapeutics US Inc. | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Merck | 1 | $15 |
| OPKO Pharmaceuticals, LLC | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
| Astellas Pharma US Inc | 1 | $14 |
| GSK | 1 | $12 |
How this compares
$1,237 in reported general payments places this provider in the 65th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $10,392 |
| JardianceEmpagliflozin | 13 | $7,491 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 22 | $802 |
| Rosuvastatin Calcium | 17 | $466 |
| Montelukast Sodium | 27 | $446 |
| Atorvastatin Calcium | 24 | $432 |
| Levothyroxine Sodium | 31 | $306 |
| Famotidine | 15 | $289 |
| Ropinirole Hcl | 11 | $259 |
| Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide | 11 | $244 |
| Furosemide | 21 | $221 |
| Losartan Potassium | 16 | $168 |
| Carvedilol | 17 | $145 |
| Metformin Hcl ErMetformin Hcl | 11 | $128 |
| Amlodipine Besylate | 14 | $120 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $12 | $10,39213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,415 family providers in Alabama.
Other family in Jasper
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
- Molly ReevesAuburn$158K
- Christina CanteyHuntsville$118K
- Leigh LunaMontgomery$69K
- Christopher LovellMobile$64K
- Justin SimpsonTuscaloosa$43K
- Kellyn McMahonBirmingham$39K
- Ashley StinesTuscaloosa$29K
- Brandy YoungMontgomery$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.